Large study finds no significant overall cancer risk increase with JAK inhibitors in RA

Regulatory authorities issued precautionary recommendations following the ORAL Surveillance trial, which demonstrated an elevated risk of cancer with tofacitinib, compared to TNF inhibitors (TNFi).

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup